CD4+CD25+ regulatory T cells as a therapeutic target in rheumatoid arthritis
CD4+CD25+ T cells are regulatory T cells (CD4+CD25+ Tregs), which can strengthen immune tolerance. They play a critical role in controlling the development of autoimmune diseases in animals and humans. Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the peripheral joints and e...
| Main Authors: | , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Polish Society of Experimental and Clinical Immunology
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439972/ |
| id |
pubmed-4439972 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-44399722015-07-07 CD4+CD25+ regulatory T cells as a therapeutic target in rheumatoid arthritis Yu, Qing Xu, Man Yu, Fang Jin, Yong Review Article CD4+CD25+ T cells are regulatory T cells (CD4+CD25+ Tregs), which can strengthen immune tolerance. They play a critical role in controlling the development of autoimmune diseases in animals and humans. Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the peripheral joints and eventually leads to joint destruction. Although the pathogenesis of RA remains unknown, it is supposed to be affected by autoreactive T cells and antibodies. At the same time, to make the CD4+CD25+ T cells active and to increase the number of the cells are responsible in the therapy of RA in recent studies. Now, many techniques about expansion of Tregs in vitro have been established to overcome the problem of their limited numbers in vivo. It is important to carry out a study of induction or amplification of Tregs in vitro. Here, we review our current understanding of CD4+CD25+ T cells in RA and the targeting of these cells in RA therapy. Polish Society of Experimental and Clinical Immunology 2014-04-17 2014 /pmc/articles/PMC4439972/ /pubmed/26155108 http://dx.doi.org/10.5114/ceji.2014.42133 Text en Copyright © Central European Journal of Immunology 2014 http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License, permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Yu, Qing Xu, Man Yu, Fang Jin, Yong |
| spellingShingle |
Yu, Qing Xu, Man Yu, Fang Jin, Yong CD4+CD25+ regulatory T cells as a therapeutic target in rheumatoid arthritis |
| author_facet |
Yu, Qing Xu, Man Yu, Fang Jin, Yong |
| author_sort |
Yu, Qing |
| title |
CD4+CD25+ regulatory T cells as a therapeutic target in rheumatoid arthritis |
| title_short |
CD4+CD25+ regulatory T cells as a therapeutic target in rheumatoid arthritis |
| title_full |
CD4+CD25+ regulatory T cells as a therapeutic target in rheumatoid arthritis |
| title_fullStr |
CD4+CD25+ regulatory T cells as a therapeutic target in rheumatoid arthritis |
| title_full_unstemmed |
CD4+CD25+ regulatory T cells as a therapeutic target in rheumatoid arthritis |
| title_sort |
cd4+cd25+ regulatory t cells as a therapeutic target in rheumatoid arthritis |
| description |
CD4+CD25+ T cells are regulatory T cells (CD4+CD25+ Tregs), which can strengthen immune tolerance. They play a critical role in controlling the development of autoimmune diseases in animals and humans. Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the peripheral joints and eventually leads to joint destruction. Although the pathogenesis of RA remains unknown, it is supposed to be affected by autoreactive T cells and antibodies. At the same time, to make the CD4+CD25+ T cells active and to increase the number of the cells are responsible in the therapy of RA in recent studies. Now, many techniques about expansion of Tregs in vitro have been established to overcome the problem of their limited numbers in vivo. It is important to carry out a study of induction or amplification of Tregs in vitro. Here, we review our current understanding of CD4+CD25+ T cells in RA and the targeting of these cells in RA therapy. |
| publisher |
Polish Society of Experimental and Clinical Immunology |
| publishDate |
2014 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4439972/ |
| _version_ |
1613226465484079104 |